Thursday, February 6, 2020

Neurocrine Biosciences Names New Board Member

San Diego-based Neurocrine Biosciences, which develops a number of biopharmaceuticals for the treatment of neurological, endocrine and psychiatric disorders, has named Shalini Sharp to its board of directors. Sharp is currently the Chief Financial Officer and Executive Vice President of Ultragenyx. Sharp was previously CFO of Agenus, and also served at Elan Pharmaceuticals, McKinsey & Company, and Goldman Sachs. Sharp also is on the boards of Sutro Biopharma and Precision Biosciences.